← Ablatotech Vitals
Nephrology EvidenceDigest

Emerging Evidence on the Use of Anti-SGLT1/SGLT2 Dual Inhibitors for Managing Proteinuria in Non-Diabetic CKD

Nephrology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 20, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Emerging evidence suggests that dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitors may reduce proteinuria and confer renal protective effects in patients with non-diabetic chronic kidney disease (CKD). While SGLT2 inhibitors alone have established benefits in diabetic and some non-diabetic CKD populations, dual SGLT1/2 inhibition offers a novel mechanism potentially enhancing proteinuria reduction and mitigating renal inflammation. However, current data remain preliminary, and robust randomized controlled trials specifically targeting non-diabetic CKD with dual inhibitors are limited. Clinicians should consider this evolving evidence as hypothesis-generating and await further validation before routine clinical adoption.

Clinical bottom line

Emerging evidence suggests that dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitors may reduce proteinuria and confer renal protective effects in patients with non-diabetic chronic kidney disease (CKD). While SGLT2 inhibitors alone have established benefits in diabetic and some non-diabetic CKD populations, dual SGLT1/2 inhibition offers a novel mechanism potentially enhancing proteinuria reduction and mitigating renal inflammation. However, current data remain preliminary, and robust randomized controlled trials specifically targeting non-diabetic CKD with dual inhibitors are limited. Clinicians should consider this evolving evidence as hypothesis-generating and await further validation before routine clinical adoption.

What the evidence shows

SGLT2 inhibitors have expanded from their original indication in type 2 diabetes to show benefits in non-diabetic CKD, including slowing disease progression and reducing proteinuria (Theodorakopoulou et al., 2023). Dual SGLT1/2 inhibitors, which block both glucose transporters in the kidney and intestine, may offer additive renal benefits by reducing glucose reabsorption more completely and modulating tubular-glomerular feedback (Patel et al., 2026).

Afrooghe Arya et al. (2022) evaluated SGLT2 inhibitors in non-diabetic patients with proteinuria, demonstrating significant reductions in proteinuria and stabilization of glomerular filtration rate (GFR). Although this study did not specifically test dual inhibitors, it supports the concept that SGLT inhibition benefits extend beyond diabetic kidney disease.

More recent mechanistic studies indicate that SGLT2 inhibition reduces mitochondrial DNA copy number in urinary cells, a marker of mitochondrial stress, in both diabetic and non-diabetic CKD patients (Lee et al., 2023). This suggests mitochondrial protection as a potential pathway for renal benefit. Dual SGLT1/2 inhibitors may enhance these effects by broader transporter blockade.

Additionally, D’Marco et al. (2026) reported that SGLT2 inhibitors ameliorate adiposopathy and systemic inflammation in CKD irrespective of diabetic status, which may contribute to renal protection. Dual inhibitors could potentially amplify anti-inflammatory effects, although direct evidence is lacking.

A systematic review and network meta-analysis by Nugroho et al. (2026) highlighted the cardiovascular and renal safety profiles of dual SGLT1/2 inhibitors, noting potential benefits in atrial fibrillation prevention, a common comorbidity in CKD. This supports the broader systemic effects of dual inhibition.

Caveats and uncertainty

The bulk of clinical trial data on dual SGLT1/2 inhibitors remains focused on diabetic populations or heart failure cohorts, with limited direct evidence in non-diabetic CKD patients. Most studies are small, short-term, or observational, limiting conclusions about long-term renal outcomes and safety.

Proteinuria reduction, while a useful surrogate, does not always translate into hard endpoints such as end-stage kidney disease or mortality. The magnitude of proteinuria reduction with dual inhibitors compared to selective SGLT2 inhibitors in non-diabetic CKD is not yet well defined.

Potential gastrointestinal side effects related to SGLT1 inhibition, such as diarrhea and malabsorption, require careful monitoring and may limit tolerability in some patients.

There is also uncertainty about which non-diabetic CKD subpopulations (e.g., glomerulonephritis, hypertensive nephropathy) might benefit most from dual inhibition, as pathophysiology varies widely.

How this may change practice

If ongoing and future trials confirm efficacy and safety, dual SGLT1/2 inhibitors could become an important adjunctive therapy for proteinuria reduction in non-diabetic CKD, potentially improving renal outcomes beyond current standards.

Clinicians should remain alert to emerging data and consider enrolling eligible patients in clinical trials investigating dual inhibitors in non-diabetic CKD.

In the interim, selective SGLT2 inhibitors remain the preferred option for non-diabetic CKD patients meeting current guideline criteria, with dual inhibitors considered experimental pending further evidence.

Integration of dual SGLT1/2 inhibitors into practice will require careful patient selection, monitoring for adverse effects, and coordination with nephrology specialists.


References

  1. Afrooghe Arya, et al. MO157: Evaluating the Effect of SGLT2 Inhibitors on Proteinuria and Glomerular Filtration Rate in Non-Diabetic Patients with Proteinuria. Nephrol Dial Transplant 2022;37(Suppl_3):gfad066.059. DOI:10.1093/ndt/gfac066.059
  2. D'Marco Luis, et al. WCN26-3855 SGLT2 Inhibitors Ameliorate Adiposopathy and Inflammation in Diabetic and Non-Diabetic CKD. Kidney Int Rep 2026;11(3):104612. DOI:10.1016/j.ekir.2026.104612
  3. LEE H., et al. WCN23-0099 SGLT2 INHIBITORS REDUCE URINARY MITOCHONDRIAL DNA COPY NUMBER IN BOTH DIABETIC AND NON-DIABETIC CKD PATIENTS. Kidney International Reports. 2023.
  4. Nugroho Heri, et al. SGLT2 inhibitors and dual SGLT1/2 inhibitors for the prevention of atrial fibrillation: A systematic review and network meta-analysis of randomized controlled trials. Tzu Chi Med J 2026;38(2):123-134. DOI:10.4103/tcmj.tcmj-d-26-00011
  5. Patel Digantkumar, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Non-diabetic Conditions Beyond Heart Failure and Chronic Kidney Disease: Emerging Evidence, Mechanisms, and Practical Considerations. Cureus 2026;18(1):e104727. DOI:10.7759/cureus.104727
  6. Theodorakopoulou Marieta P, et al. SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future? Clin Kidney J 2023;16(1):1-9. DOI:10.1093/ckj/sfad272

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team